1 March 2026 - The March 2026 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The March issue of the Schedule includes has a few new/revised listings of note:

• Aflibercept (Eylea) - new formulation
• Aripiprazole monohydrate (Abilify Maintena) - new formulation
• Bimekizumab (Bimzelx) - new strength
• Botulinum toxin type A (Xeomin) - new indication
• Denosumab (Osenvelt, Stoboclo) - new biosimilar medicine 
• Enoxaparin sodium (Enoxaject) - new biosimilar medicine
• Etanercept (Nepexto) - new formulation
• Glofitamab (Columvi) - new medicine
• Ipilimumab (Yervoy) - restriction change
• Nivolumab (Opdivo) - restriction change
• Pioglitazone hydrochloride (Actos) - restriction change
• Ravulizumab (Ultomiris) - new indication

Read summary of PBS changes